Fig. 2

The CCR8 antagonist IPG0521 suppresses murine liver cancer growth via elevating CD8⁺ T cells without Treg reduction or depletion. A Binding activity of IPG0521 on CCR8-293 T with FCM analysis. B The specific binding of IPG0521 with mouse CCR8-CHOK1, rat CCR8-293 T, dog CCR8-293 T, and cynomolgus CCR8-293 T. Parental HEK293 cells were used as control. C Representative inhibition of IPG0521m in mCCL1 (100 ng/ml) mediated chemotaxis of Treg cells isolated from the tumor tissues of H22 syngeneic liver cancer model. D Dose-dependent inhibition of the syngeneic liver cancer growth in response to IPG0521m treatment. P values were calculated with tumor volume on day 19 after grouping using Tukey's multiple comparisons test. E–F Changes in tumor weight and size in response to different doses of IPG0521m administration. G-L Proportions of tumor-infiltrating CD45⁺ cells (G), CD8⁺ T cells (H), CD4⁺ T cells (I), total Tregs (J), CCR8⁺ Tregs in total CD45⁺ cells (K), and CCR8⁺ Tregs in total Tregs (L) with or without IPG0521m treatment (3 mg/kg). M RNA-seq analysis showing major changes in gene expression with or without IPG0521m treatment (3 mg/kg). Data were shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, compared to control